Ambit Biosciences Announces Compound Profiling Collaboration with Pfizer.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Ambit (language) AMBIT - Algebraic Manipulation by Identity Translation (also claimed: "Acronym May Be Ignored Totally"). An early pattern-matching language, developed by C. Christensen of Massachusetts Computer Assocs in 1964, aimed at algebraic manipulation. Biosciences today announced that it has entered into an expanded compound profiling collaboration with Pfizer's La Jolla La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and laboratories. Under the collaboration, Ambit will employ its proprietary "Reverse Screening" technology to identify and characterize the protein targets of certain Pfizer drug discovery compounds and thereby elucidate e·lu·ci·date v. e·lu·ci·dat·ed, e·lu·ci·dat·ing, e·lu·ci·dates v.tr. To make clear or plain, especially by explanation; clarify. v.intr. To give an explanation that serves to clarify. their molecular mechanism of action. "Our proprietary 'Reverse Screening' technology enables us to determine mechanism of action by screening small molecules across a large fraction of all human proteins. Knowing mechanism of action can improve and accelerate the process of advancing drug candidates into clinical development," explained Scott Salka, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Ambit. "Ambit has utilized this technology internally to develop our small molecule neuroprotectants for the treatment of stroke and other CNS See Continuous net settlement. CNS See continuous net settlement (CNS). disorders, and we look forward to utilizing it externally as well through this collaboration with Pfizer. Having Pfizer located here in San Diego is great for the local biotech community and has certainly aided us in developing relationships with Pfizer scientists." "The earnings generated from our partnerships, including our existing multi-year collaboration with Roche, will support the continued development of Ambit's pipeline of drug candidates for the treatment of stroke and various cancers, the first of which we plan to advance into clinical trials during 2005," Salka added. About Ambit Biosciences Ambit Biosciences is a privately-held biopharmaceutical company developing small molecule neuroprotectants for the treatment of stroke and other CNS disorders and kinase inhibitors for the treatment of cancers. Ambit plans to initiate clinical trials for stroke in 2005 and oncology in early 2006. Ambit's proprietary technology, which has been validated through collaborations with Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Company, GlaxoSmithKline, Pfizer and Roche, provides an unprecedented ability to identify, characterize, and quantify protein-small molecule interactions. Ambit has raised a total of nearly $50 million from investors including Perseus-Soros Biopharmaceutical Fund, Forward Ventures, Roche, Avalon Ventures and GIMV NV. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion